Claims for Patent: 10,232,015

Summary for Patent: 10,232,015

Title:	Sugar compositions for treating hemophilia A and/or Von Willebrand disease
Abstract:	The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
Inventor(s):	Schulte; Stefan (Marburg, DE), Spirig; Rolf (Bern, CH), Zollner; Sabine (Muri, CH), Moses; Michael (Graevenwiesbach, DE), Wormsbaecher; Wilfried (Kirchhain, DE), Stoehr; Hans-Arnold (Wetter, DE)
Assignee:	CSL BEHRING GMBH (Marburg, DE)
Application Number:	15/622,447
Patent Claims:	1. A method of increasing the half-life of von Willebrand factor in the blood of a subject with hemophilia A and/or von Willebrand disease, comprising administering to the subject a composition comprising an isolated sugar that inhibits the interaction of von Willebrand factor with its clearance receptor, wherein the sugar is a glycopeptide comprising an accessible sugar residue derived from ABO(H) blood group antigen, and wherein the accessible sugar residue is attached to the glycopeptide by the same type of linkage as present in the blood group antigen. 2. The method of claim 1, wherein the in vivo clearance of von Willebrand factor is reduced. 3. The method of claim 2, wherein the reduction of in vivo clearance of von Willebrand factor leads to a concomitant increase in the area under the curve representing factor VIII concentration. 4. The method of claim 2, wherein the von Willebrand factor is endogenously produced. 5. The method of claim 1, wherein the method further comprises administering exogenous von Willebrand factor. 6. The method of claim 5, wherein the exogenous von Willebrand factor is plasma-derived. 7. The method of claim 5, wherein the exogenous von Willebrand factor is recombinant. 8. The method of claim 5, wherein the composition is administered to a subject prior to administration of exogenous von Willebrand factor. 9. The method of claim 1, wherein the sugar is an asialo-glycopeptide, or chemically modified derivative thereof. 10. The method of claim 1, wherein the clearance receptor is a C-type lectin-like receptor. 11. The method of claim 10, wherein the C-type lectin-like receptor is selected from the subgroups asialoglycoprotein, DC receptors, and collectins. 12. The method of claim 10, wherein the C-type lectin-like receptor is selected from ASGPR, CLEC4M, CLEC10A, CLEC4F, and Collectin-12. 13. The method of claim 1, wherein the clearance receptor is a class A scavenger receptor comprising scavenger receptor A5 (SCARA5). 14. A method of increasing the half-life of von Willebrand factor in the blood of a subject with hemophilia A and/or von Willebrand disease, comprising administering to the subject a composition comprising von Willebrand factor and an isolated sugar that inhibits the interaction of von Willebrand factor with its clearance receptor, wherein the sugar is a glycopeptide comprising an accessible sugar residue derived from ABO(H) blood group antigen, and wherein the accessible sugar residue is attached to the glycopeptide by the same type of linkage as present in the blood group antigen. 15. The method of claim 14, wherein the in vivo clearance of von Willebrand factor is reduced. 16. The method of claim 15, wherein the reduction of in vivo clearance of von Willebrand factor leads to a concomitant increase in the area under the curve representing factor VIII concentration. 17. The method of claim 14, wherein the administered von Willebrand factor is recombinant. 18. The method of claim 14, wherein the sugar is an asialo-glycopeptide, or chemically modified derivative thereof. 19. The method of claim 14, wherein the clearance receptor is a C-type lectin-like receptor. 20. The method of claim 14, wherein the clearance receptor is a class A scavenger receptor comprising scavenger receptor A5 (SCARA5).

Details for Patent 10,232,015

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	December 08, 2015		2037-06-14